Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Ming-Shu HsiehNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Chia-Wei HsuNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Hung-Chun LiaoNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Chang-Ling LinNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Chen-Yi ChiangNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Mei-Yu ChenNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Shih-Jen LiuNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Ching-Len LiaoNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Hsin-Wei ChenNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.ORCID 0000-0002-3207-2397
National Health Research Institutes · TWKaohsiung Medical University · TW
Funding
National Health Research Institutes (NHRI) IV-110-PP-15, IV-111-PP-18National Science and Technology Council (NSTC) NSTC 112-2320-B-400-021
6 · The paper itself
Abstract
Vaccine-induced mucosal immunity and broad protective capacity against various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remain inadequate. Formyl peptide receptor-like 1 inhibitory protein (FLIPr), produced by
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters. · full record | OpenQuestion